Nurix Therapeutics, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • ADMET

Other Names/Subsidiaries

  • DeCART Therapeutics
  • Nurix, Inc.
See more in Biomedtracker

Latest on Nurix Therapeutics, Inc.

Scrip

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa

Scrip

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D

Scrip

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Scrip

Gilead and Leo Pact Adds Fuel To Hot STAT6 Inflammation Space

 
• By Kevin Grogan

Gilead Sciences' acquisition of Leo Pharma’s signal transducer and activator of transcription 6 (STAT6) program is not just a major boost for the Danish group’s finances but also a nod to the growing